Discovery of an Orally Available Potent ER Aminopeptidase 1 (ERAP1) Inhibitor That Enhances Antitumor Responses and Limits Inflammatory Autoimmunity In Vivo

Journal of Medicinal Chemistry 2026

View at publisher
Authors: Christopher P. Tinworth, Justyna Wojno-Picon, Michael Adam, Stephan Gade, Ashley P. Hancock, David J. Hirst, Jonathan P. Hutchinson, Su Kitchen, Despoina Koumantou, Jonathan Lea, Stephanie Lehmann, John Liddle
+20 more Richard Lonsdale, Margarete Neu, Leng Nickels, Alex Phillipou, James E. Rowedder, Paul Rowland, Jessica L. Schneck, Paul Scott-Stevens, Hester Sheehan, Michael Steidel, Chloe L. Tayler, Ioannis Temponeras, Kevin Thang, David F. Tough, Giovanni Vitulli, Ian D. Wall, Robert J. Young, Nico Zinn, Simon Peace, Efstratios Stratikos
DOI: 10.1021/acs.jmedchem.6c00029
Cited by: 1
References: 80

Abstract

tools for interrogating ERAP1 biology and further drug development.

Fields of Study & Subjects

Spondyloarthritis Studies and Treatments Peptidase Inhibition and Analysis Inflammasome and immune disorders

Publication details

Journal / source
Journal of Medicinal Chemistry
Publisher
American Chemical Society (ACS)
Volume
69
Issue
13
Pages
15358–15373
Publication date
22 June 2026
Language
EN